456 related articles for article (PubMed ID: 29082448)
1. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
[TBL] [Abstract][Full Text] [Related]
2. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
4. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
6. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
Ashraf M; Souka AA; ElKayal H
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
[TBL] [Abstract][Full Text] [Related]
7. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
8. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
[TBL] [Abstract][Full Text] [Related]
9. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
10. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs.
Ibrahim WS; Eldaly ZH; Saleh MG; Rateb MF; Aldoghaimy AH
Korean J Ophthalmol; 2019 Apr; 33(2):122-130. PubMed ID: 30977321
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
12. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Macular Thickness and Visual Acuity in DME Treated by Two Doses of Intravitreal Ziv-Aflibercept Versus Bevacizumab: Analysis of a Randomized, Three-Armed Clinical Trial.
Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):684-690. PubMed ID: 31755967
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema.
Ashraf M; Kayal HE; Souka AAR
Ophthalmic Surg Lasers Imaging Retina; 2017 May; 48(5):399-405. PubMed ID: 28499051
[TBL] [Abstract][Full Text] [Related]
15. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions.
Hanhart J; Rozenman Y
Ophthalmologica; 2017; 238(1-2):110-118. PubMed ID: 28535531
[TBL] [Abstract][Full Text] [Related]
17. Sequential Dexamethasone and Aflibercept Treatment in Patients with Diabetic Macular Edema: Structural and Functional Outcomes at 52 Weeks.
Hernández-Bel L; Cervera-Taulet E; Navarro-Palop C; Castro-Navarro V; Chiarri-Toumit C; Montero-Hernández J
Ophthalmologica; 2019; 241(2):98-104. PubMed ID: 29996128
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
20. The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections.
Yolcu Ü; Sobaci G
Int Ophthalmol; 2015 Feb; 35(1):73-9. PubMed ID: 25425105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
